SU101

SU101 is a cancer treatment drug that is currently under investigation. It is a signal transduction inhibitor, which means it works by blocking signals that tell cancer cells to grow and divide. SU101 is also known as Semaxanib or SU5416.

Mechanism of Action

SU101 inhibits the vascular endothelial growth factor receptor (VEGFR), a protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By blocking VEGFR, SU101 can prevent the growth of new blood vessels that tumors need to grow and spread.

Clinical Trials

SU101 has been tested in several clinical trials for various types of cancer, including glioblastoma, renal cell carcinoma, and colorectal cancer. While some trials have shown promising results, others have not, and further research is needed to determine the drug's effectiveness and safety.

Side Effects

Like all drugs, SU101 can cause side effects. These can include nausea, vomiting, fatigue, and pain. In some cases, the drug can also cause more serious side effects, such as bleeding, infection, and heart problems.

Future Research

Future research on SU101 will likely focus on determining the most effective dosages and treatment schedules, as well as identifying which patients are most likely to benefit from the drug. Researchers may also investigate combining SU101 with other treatments to increase its effectiveness.

See Also

• Cancer treatment
• Clinical trial
• Angiogenesis
• Vascular endothelial growth factor receptor